Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious and rare diseases.
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed serious and rare diseases with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious condition, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Cardiometabolic Lipid Disorders
These disorders are complex, with a multitude of risk factors related to many diseases, rare and relatively common, including pancreatitis, diabetes, liver disease, and multiple forms of cardiovascular disease.
Hereditary Transthyretin (TTR) Amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.
October 08, 2018
Akcea Announces Changes to Board of Directors
Learning about hereditary transthyretin (TTR) amyloidosis
TTR amyloidosis (ATTR) is a rare, progressive and fatal genetic disease that currently only has limited treatment options that do not treat the underlying cause of disease.Visit hattrchangethecourse.com
Learning about familial chylomicronemia syndrome (FCS)
FCS is a severe and rare disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitisVisit FCSFocus.com